Back to search results

Study of JNJ-86974680 for Advanced Non-small Cell Lung Cancer

This study is testing a new drug called JNJ-86974680. It will be given along with cetrelimab and radiation therapy to people with advanced non-small cell lung cancer (NSCLC). The main goal is to find a safe and tolerable dose of JNJ-86974680 when combined with these other treatments. Researchers will be looking for side effects and how well participants tolerate the treatment. You may be able to join if you have stage IIIB-IV NSCLC and certain genetic changes (like EGFR, ALK, ROS1, or BRAF) have been identified in your cancer. This study is currently recruiting participants.

Study design
This is an interventional study planning to enroll 126 participants. It involves different parts, including dose escalation and dose expansion.
What's involved
The study involves a screening period, a treatment period, a post-treatment follow-up, and a long-term extension period. Specific details about visits or procedures are not provided.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events and dose-limiting toxicities for up to 2 years and 5 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06116786

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
Johnson & Johnson Enterprise Innovation Inc.
~67 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:JNJ-86974680CetrelimabRadiation Therapy

At a glance

Recruiting sites
0 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Adverse Events (AEs) by Severity
Measured over Up to 2 years 5 months
+1 more outcome measured

Conditions

Carcinoma, Non-small-Cell Lung

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

15 sites across 9 states
Spain4
New York2
Germany2
South Korea2
Georgia1
New Jersey1
Oregon1
Pennsylvania1

Study leadership

  • Johnson & Johnson Enterprise Innovation, Inc Clinical Trial · STUDY_DIRECTOR · Johnson & Johnson Enterprise Innovation Inc.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)
Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \[EGFR\], anaplastic lymphoma kinase \[ALK\], c-ros oncogene 1 \[ROS1\], v-raf murine sarcoma viral oncogene homolog B1 \[BRAF\]) must have received all approved targeted therapies and have progressed
Part 2: No targetable mutations (for example, EGFR \[epidermal growth factor receptor\], ALK \[anaplastic lymphoma kinase\], ROS1\[c-ros oncogene 1\], and BRAF \[B-Raf proto-oncogene, serine/threonine kinase\])
Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy
For Cohort B of Part 2: Previously treated with anti-PD-1/PD-L1 therapy for metastatic disease as the prior line of therapy
For Cohort C of Part 2: Treatment naïve
Adequate organ function

Exclusion

Active central nervous system (CNS) disease involvement
Active autoimmune disease
Active infection
History of solid organ or hematologic stem cell transplantation

What this trial measures

  • Number of Participants with Adverse Events (AEs) by SeverityUp to 2 years 5 months

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

  • Number of Participants with Dose Limiting Toxicities (DLTs)Up to 2 years 5 months

    The DLTs are specific adverse events and are defined as any of the following: non-hematologic toxicity and hematological toxicity.